Pancreatic cancer, which maintains a 95% mortality rate, is resistant to all current treatments. Patients have extremely poor chances of surviving for five years after being diagnosed—and since the disease does not show symptoms until the advanced stages, it is notoriously hard to diagnose.

However, this new Tel Aviv University study finds that a small molecule has the ability to induce the self-destruction of pancreatic cancer cells. The research was conducted with xenografts—transplantations of human pancreatic cancer into immunocompromised mice. The treatment reduced the number of cancer cells by 90% in the developed tumors a month after being administered.

The research holds great potential for the development of a new effective therapy to treat this aggressive cancer in humans.

WATCH: He Was Called Foolish for His Research; Now Documentary Tells How He Won Nobel Prize for 'Cancer Cure'

The study, which was published in the journal Oncotarget, was led by Professor Malca Cohen-Armon and her team at TAU's Sackler Faculty of Medicine, in collaboration with Dr. Talia Golan's team at the Cancer Research Center at Sheba Medical Center.

"In research published in 2017, we discovered a mechanism that causes the self-destruction of human cancer cells during their duplication without affecting normal cells," explains Prof. Cohen-Armon. "We have now harnessed this information to efficiently eradicate human pancreatic cancer cells in xenografts. The current results were obtained using a small molecule that evokes this self-destruction mechanism in a variety of human cancer cells.